Mounjaro is cleared by the FDA to improve blood sugar in adults with type 2 diabetes
Most patients notice modest weight losstypically 1-4% of their starting body weightin the first month
Retatrutide has not yet been studied in a dedicated sleep apnea trial, but given its greater weight loss, the expectation is that sleep apnea improvements would be at least as significant as those seen with tirzepatide, possibly more so
According to FDA prescribing information, semaglutide has a half-life of approximately one week, meaning it remains in the system for several weeks after the last dose, but this persistence does not translate to detection on standard laboratory work
May help with weight loss: Semaglutide helps reduce appetite and increases feelings of fullness, leading to less food consumption
Effects of intraduodenal glutamine on incretin hormone and insulin release, the glycemic response to an intraduodenal glucose infusion, and antropyloroduodenal motility in health and type 2 diabetes